Intellia Therapeutics Inc(NTLA)今日盘中大涨8.06%,引发了市场广泛关注。导致此次股价上涨的主要原因是该公司发布了令人鼓舞的2024年第四季度财报数据。
根据最新财报,NTLA在2024年第四季度录得销售额1287万美元,高于分析师预期的853万美元,同比去年增长771.57%。尽管公司仍处于亏损状态,但每股亏损1.27美元好于分析师预期的1.36美元亏损,同比去年减亏13.01%。
作为一家基因编辑公司,NTLA专注于开发治疗基因定义疾病的CRISPR/Cas9疗法,具有广阔的发展前景。其财报体现出产品管线取得积极进展,收入增长强劲,成本控制良好。因此在机构看来,NTLA长期增长潜力巨大,多数分析师对其持偏好评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.